Increased risk for men with T2D

In recent years, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been widely used in the treatment of type 2 diabetes, as they not only provide improved glycemic control, but also offer cardiovascular and nephroprotective benefits. However, SGLT2i cause glycosuria, which can lead to infection and inflammation in the microenvironment of the foreskin. To date, very little data is available on the risk of these specific complications.